Pasar al contenido principal

NOVEL METHODS FOR KINETIC MODELLING AND PARAMETRIC IMAGING IN TOTAL-BODY PET

PID2022-138183OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PET biodistribution study of subcutaneous and intravenous administration of adalimumab in an inflammatory bowel disease model

  • Codesido, Jessica
  • García-Varela, Lara
  • García-Otero, Xurxo
  • Bouzón-Barreiro, Sheila
  • Gómez-Lado, Noemí
  • Toja-Camba, Francisco José
  • Mondelo-García, Cristina
  • Lazaré, Héctor
  • Baguña Torres, Júlia
  • Vidal-Otero, Jana
  • Medin-Aguerre, Santiago
  • Sanchez-Crespo, Alejandro
  • Otero-Espinar, Francisco J.
  • Herance, José R.
  • Fernández-Ferreiro, Anxo
  • Aguiar, Pablo
Monoclonal antibodies targeting tumor necrosis factor-alpha (antiTNF-α) are used for patients with immuno-mediated illness as inflammatory bowel disease (IBD). However, 20–40 % of IBD patients do not respond to these therapies, and increasing knowledge of biodistribution could optimize their use and consequently their effectiveness. The aim of this study is to compare the biodistribution of adalimumab after intravenous (IV) and subcutaneous (SC) administration using Positron Emission Tomography (PET) imaging in IBD animal models. IBD was induced in mice using oral dextran sulfate sodium (DSS) and each induced animal was individually confirmed using [18F]FDG PET/CT scans, weight monitoring and histopathological analysis of colon tissue samples. The SC and IV biodistribution pharmacokinetics profiles and in vivo biodistribution of adalimumab labeled with 89Zr were evaluated using a dedicated PET/CT scanner. Mean standardized uptake values (SUV) were estimated from the colon, liver, and blood over seven days. Blood analysis revealed faster elimination of adalimumab in IBD models compared to controls, and after IV compared to SC administration (SUV 168 h p.i. SC-IBD = 0.06 ± 0.02, SC-Control = 1.08 ± 0.11, IV-IBD = 0.02 ± 0.01, IV-Control = 0.26 ± 0.13). Furthermore, IBD models exhibited faster whole-body clearance than controls and an earlier and higher concentration peak of adalimumab in the colon after IV (SUV 6 h p.i. IBD-IV = 2.11 ± 0.18) compared to SC administration (SUV 24 h p.i. IBD-SC = 1.49 ± 0.27). Our findings demonstrate the significant influence of the administration route and the TNF-α expression (local and also systemic) on the amount of adalimumab reaching the colon over time., This work was partially supported by Instituto de Salud Carlos III (ISCIII, Spain) through PI20/00719 project, Axencia Galega de Innovacion (Grupos de Potencial Crecimiento IN607B2020/11, Spain), Ministry of Science and Innovation of Spain (MICINN, Spain) through PID2022-138183OB-I00 project. J. Codesido is grateful to the Health Research Institute of Santiago de Compostela (IDIS, Spain) for financing his predoctoral research fellowship and X. García-Otero acknowledges the support of Xunta de Galicia (Spain) through the postdoctoral fellowship [ED481B-2023-063]., No